skip link
skip to main content
About Us
Back
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Back
Platform Technology
Science
Posters
Publications
PIPELINE
Investors & media
Back
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Fillings
Governance Documents
CONTACT US
Perspectives
Sign Up
subpage banner
2024 NEWS RELEASE
Display #
5
10
15
20
25
30
50
100
All
Articles
Title
Author
Hits
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
Gain Therapeutics Announces Proposed Public Offering
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Page 1 of 3
1
2
3
©2023 Gain Therapeutics, Inc.
Website by Sandman Media Inc.